Nexlizet

Chemical Namebempedoic acid and ezetimibe
Dosage FormTablet (oral; 180 mg bempedoic acid/10 mg ezetimibe)
Drug ClassInhibitors
SystemCardiovascular
CompanyEsperion
Approval Year2020

Indication

  • Indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C
Last updated on 4/23/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nexlizet (bempedoic acid and ezetimibe) Prescribing Information. 2020Esperion Therapeutics, Inc., Ann Arbor, MI
Document TitleYearSource
VA/DoD clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction. 2020Department of Veterans Affairs Department of Defense